Development and Validation of a Stability-Indicating Liquid Chromatographic Method for Estimating Olmesartan Medoxomil Using Quality by Design
Open Access
- 12 January 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 53 (7) , 1048-1059
Abstract
The current studies entail systematic quality by design (QbD)-based development of a simple, rapid, sensitive and cost-effective stability-indicating method for the estimation of olmesartan medoxomil. Quality target method profile was defined and critical analytical attributes (CAAs) for the reverse-phase liquid chromatography method earmarked. Chromatographic separation accomplished on a C18 column using acetonitrile and water (containing 0.1% orthophosphoric acid, pH 3.5) in 40 : 60 (v/v) as mobile phase at a flow rate of 1.0 mL/min with UV detection at 243 nm. Risk assessment studies and screening studies facilitated comprehensive understanding of the factors affecting CAAs. The mobile phase ratio and flow rate were identified as critical method parameters (CMPs) and were systematically optimized using face-centered cubic design, evaluating for CAAs, namely peak area, retention time, theoretical plates and peak tailing. Statistical modelization was accomplished followed by response surface analysis for comprehending plausible interaction(s) among CMPs. Search for optimum solution was conducted through numerical and graphical optimization for demarcating the design space. Analytical method validation and subsequent forced degradation studies corroborated the method to be highly efficient for routine analysis of drug and its degradation products. The studies successfully demonstrate the utility of QbD approach for developing the highly sensitive liquid chromatographic method with enhanced method performance.Keywords
This publication has 30 references indexed in Scilit:
- The paradigm shifting role of chromatographic methods in pharmaceutical analysisJournal of Pharmaceutical and Biomedical Analysis, 2012
- DEVELOPMENT OF A STABILITY-INDICATING UPLC METHOD FOR DETERMINATION OF OLMESARTAN MEDOXOMIL AND ITS DEGRADATION PRODUCTS IN ACTIVE PHARMACEUTICAL INGREDIENT AND DOSAGE FORMSJournal of Liquid Chromatography & Related Technologies, 2012
- The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover studyClinical Therapeutics, 2010
- RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditionsActa Pharmaceutica, 2010
- DEVELOPMENT OF LLE AND SPE PROCEDURES AND ITS APPLICATIONS FOR DETERMINATION OF OLMESARTAN IN HUMAN PLASMA USING RP-HPLC AND HPTLCJournal of Liquid Chromatography & Related Technologies, 2010
- LC–MS–MS Determination of Olmesartan in Human PlasmaChromatographia, 2007
- Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometryJournal of Chromatography B, 2007
- Olmesartan medoxomil: current status of its use in monotherapyVascular Health and Risk Management, 2006
- The new oral angiotensin II antagonist olmesartan medoxomil: a concise overviewJournal of Human Hypertension, 2002
- The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interactionJournal Of Hypertension, 2001